Bębnowska Dominika, Hrynkiewicz Rafał, Grywalska Ewelina, Pasiarski Marcin, Sosnowska-Pasiarska Barbara, Smarz-Widelska Iwona, Góźdź Stanisław, Roliński Jacek, Niedźwiedzka-Rystwej Paulina
Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland.
Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland.
Int J Mol Sci. 2021 Mar 30;22(7):3587. doi: 10.3390/ijms22073587.
Multiple myeloma (MM) is a plasma cell neoplasm characterized by an abnormal proliferation of clonal, terminally differentiated B lymphocytes. Current approaches for the treatment of MM focus on developing new diagnostic techniques; however, the search for prognostic markers is also crucial. This enables the classification of patients into risk groups and, thus, the selection of the most optimal treatment method. Particular attention should be paid to the possible use of immune factors, as the immune system plays a key role in the formation and course of MM. In this review, we focus on characterizing the components of the immune system that are of prognostic value in MM patients, in order to facilitate the development of new diagnostic and therapeutic directions.
多发性骨髓瘤(MM)是一种浆细胞肿瘤,其特征为克隆性、终末分化的B淋巴细胞异常增殖。目前MM的治疗方法主要集中在开发新的诊断技术;然而,寻找预后标志物也至关重要。这有助于将患者分类为不同风险组,从而选择最优化的治疗方法。应特别关注免疫因子的可能用途,因为免疫系统在MM的形成和病程中起关键作用。在本综述中,我们着重描述在MM患者中具有预后价值的免疫系统组成部分,以促进新的诊断和治疗方向的发展。